| pubmed-article:19160079 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19160079 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:19160079 | lifeskim:mentions | umls-concept:C0016911 | lld:lifeskim |
| pubmed-article:19160079 | lifeskim:mentions | umls-concept:C1619692 | lld:lifeskim |
| pubmed-article:19160079 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:19160079 | lifeskim:mentions | umls-concept:C0009924 | lld:lifeskim |
| pubmed-article:19160079 | lifeskim:mentions | umls-concept:C2347946 | lld:lifeskim |
| pubmed-article:19160079 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19160079 | pubmed:dateCreated | 2009-2-20 | lld:pubmed |
| pubmed-article:19160079 | pubmed:abstractText | Human nephrogenic systemic fibrosis (NSF) is a rare condition reported in patients with severe renal insufficiency exposed to a gadolinium (Gd)-based contrast agent. An animal model of NSF could help to investigate its mechanisms and lead to prevention and treatment. | lld:pubmed |
| pubmed-article:19160079 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19160079 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19160079 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19160079 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19160079 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19160079 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19160079 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19160079 | pubmed:issn | 1600-0455 | lld:pubmed |
| pubmed-article:19160079 | pubmed:author | pubmed-author:GrantDD | lld:pubmed |
| pubmed-article:19160079 | pubmed:author | pubmed-author:LøvhaugDD | lld:pubmed |
| pubmed-article:19160079 | pubmed:author | pubmed-author:JohnsenHH | lld:pubmed |
| pubmed-article:19160079 | pubmed:author | pubmed-author:JuelsrudAA | lld:pubmed |
| pubmed-article:19160079 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19160079 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:19160079 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19160079 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19160079 | pubmed:pagination | 156-69 | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:meshHeading | pubmed-meshheading:19160079... | lld:pubmed |
| pubmed-article:19160079 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19160079 | pubmed:articleTitle | Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. | lld:pubmed |
| pubmed-article:19160079 | pubmed:affiliation | GE Healthcare, Medical Diagnostics, Oslo, Norway. derek.grant@ge.com | lld:pubmed |
| pubmed-article:19160079 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19160079 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
